Michael is head of the operations group at AOP Orphan. He assumed this position in the beginning of 2012 and he is responsible for a team of 9 people and the overall delivery of the conducted studies. The group runs several studies in different indications with a clear focus on rare diseases. In 2016 AOP Orphan received approval for one new product, and filed the EMA application for another one, outlining the highly productive R&D activities.
Before joining AOP Orphan Michael has been operations manager for Hemophilia at Baxter GmbH. Michael has many years of experience as a project manager, being responsible for all aspects - timelines, budget, and quality. Michael also organized numerous investigators meetings, safety board meetings and is a speaker at several pharmaceutical meetings.
He started his career as a CRA at Amgen in Austria, locally responsible for implementation of trials with new biologicals, mainly monoclonal antibodies.
Michael received his Ph. D in biochemistry from the University of Vienna. In addition he held a teaching position at the University of Vienna.